BioWorld - Sunday, December 15, 2019

Financings, BioWorld Asia
%{topic} RSS Feed RSS

China’s Clover completes $43M series B

December 10, 2019
By Elise Mak
No Comments
BEIJING – Chengdu-based Sichuan Clover Biopharmaceuticals Inc. closed a series B financing round to inject another $43 million into its drug development and manufacturing operations, with a focus on biologic candidate SCB-313, developed with its Trimer-Tag technology platform.
Read More

Emphasizing synergy and efficiency, EOC Pharma raises $71M series C to fight breast, gastric cancers

December 10, 2019
By Elise Mak
No Comments
BEIJING – EOC Pharmaceutical Group, of Shanghai, completed a series C financing round, bagging $71 million to advance its lead programs EOC-103 and EOC-315 for breast and gastric cancers. The round was led by Hangzhou Tigermed Consulting Co. Ltd. and its affiliated funds, TF Capital and Yingke PE. Hanne Capital and Everest Venture Capital also participated in the round. In 2017, EOC raised $32 million in a series B round. All funding participants are China-based.
Read More

Tot Biopharm raises $61M on HKEX, co-develops antibody with Harbour

November 12, 2019
By Elise Mak
No Comments
BEIJING – Chinese clinical-stage cancer drug developer Tot Biopharm International Co. Ltd. went public on Hong Kong's stock exchange under the stock code of 1875 on Friday, raising HK$511.4 million (US$61.3 million) by issuing shares at HK$6.55 apiece. But its debut met with an unexpected setback, with share prices down nearly 7% in mid-morning. Prior to the listing, the company said its shares were oversubscribed by around 11.95 times and it "was well received by the capital market."
Read More
chinese yuan

Akeso closes $150M series D to advance first-in-class bispecific antibodies

November 7, 2019
By Elise Mak
No Comments
BEIJING – Antibody developer Akeso Biopharma Inc., from China's Guangdong province, closed a $150 million series D financing round to advance its pipeline, especially the two PD-1-based bispecific antibodies, AK-104 and AK-112, aimed to help it stand out in the fierce PD-1 space in China. "A significant portion of the proceeds will go to AK-104 and AK-112, which are both first-in-class drug candidates," Akeso CEO Michelle Xia told BioWorld. This year is a big one for Akeso, as AK-104 and AK-112 received IND approvals from the FDA in March and July, respectively.
Read More

Popular Stories

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe